Search

Your search keyword '"Tafuri, Agostino"' showing total 947 results
Start Over Author "Tafuri, Agostino"
947 results on '"Tafuri, Agostino"'

202. Severe and Prolonged Myelosuppression during Concomitant Temozolomide and Radiotherapy Treatment in a Patient with Glioblastoma Multiforme

Author

Scaringi, Claudia, primary, Sanctis, Vitaliana, additional, Minniti, Giuseppe, additional, Porrini, Raffaele, additional, Carnevale, Alessia, additional, Valeriani, Maurizio, additional, Cox, Maria, additional, Spiriti, Maria, additional, Gentile, Giovanna, additional, Simmaco, Maurizio, additional, Ruco, Luigi, additional, Tafuri, Agostino, additional, and Enrici, Riccardo, additional

Published
2015
Full Text
View/download PDF

208. Incidence of Infectious Complications in MDS/AML Patients Treated with Azacitidine By the Italian Cooperative Groups Gruppo Romano MDS (GROM) and Basilicata MDS Registry

Author

Voso, Maria Teresa, primary, Niscola, Pasquale, additional, Piciocchi, Alfonso, additional, Pagano, Livio, additional, Maurillo, Luca, additional, Musto, Pellegrino, additional, Fianchi, Luana, additional, Mansueto, Giovanna, additional, Aloe-Spiriti, Antonietta, additional, Buccisano, Francesco, additional, Venditti, Adriano, additional, Tendas, Andrea, additional, Mancini, Stefano, additional, Piccioni, Anna Lina, additional, Andriani, Alessandro, additional, Latagliata, Roberto, additional, Alimena, Giuliana, additional, Filardi, Nunzio, additional, Fragasso, Alberto, additional, Tafuri, Agostino, additional, Fenu, Susanna, additional, and Breccia, Massimo, additional

Published
2014
Full Text
View/download PDF

214. Targeting the Raf/MEK/ERK pathway with small molecule inhibitors

Author

Mccubrey, Ja, Milella, M, Tafuri, Agostino, Martelli, Am, Lunghi, P, Bonati, A, and Steelman, Ls

Subjects
apoptosis, cancer, ERK, inhibitor, MEK, Raf, signal transduction, inhibitor, ERK, apoptosis, cancer, Raf, MEK, signal transduction
Published
2008

217. ERK1/2 phosphorylation in adult acute lymphoblastic leukemia patients: prognostic role and in vitro effects of MEK inhibition

Author

Gregorj, C, Ricciardi, Maria Rosaria, Petrucci, Mt, Scerpa, Mc, De Cave, F, Fazi, P, Vitale, A, Mancini, M, Cimino, Giuseppe, Palmieri, S, Di Raimondo, F, Specchia, G, Fabbiano, F, Cantore, N, Mosna, F, Camera, A, Luppi, M, Annino, L, Miraglia, E, Fioritoni, G, Ronco, F, Meloni, G, Andreeff, M, Milella, M, Mandelli, Franco, Foà, R, and Tafuri, Agostino

Published
2006

218. BREAST CANCER RESISTANCE PROTEIN (BCRP) EXPRESSION AFFECT EVENT-FREE SURVIVAL IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS

Author

Gregorj, C, DE CAVE, Fabiana, Petrucci, Mt, Ricciardi, Maria Rosaria, Scerpa, Mc, Vignetti, M, Vitale, A, Meloni, G, Liso, V, Di Raimondo, F, Ferrara, F, Fabbiano, F, Camera, A, Fioritoni, G, Miraglia, E, Annino, L, Cascavilla, N, Marmont, F, Mazza, P, Perbellini, O, Cartore, N, Luppi, M, Nobile, F, Sica, S, Salvi, F, Mandelli, Franco, Foà, R., and Tafuri, Agostino

Published
2006

222. Role of extracellular signal-regulated kinase-1/2 (ERK) on complete remission achievement of primary adult acute lymphoblastic leukemia patients enrolled in the GIMEMA protocol LAL 2000: in vitro activity of the MEK inhibitor PD98059

Author

Gregorj, C, Petrucci, Mt, Scerpa, Mc, Ricciardi, Maria Rosaria, De Cave, F, Gervasoni, J, Vignetti, M, Gubbiotti, Stefania, Ariola, C, Specchia, G, Chiarenza, A, Ferrara, F, Fabbiano, F, Camera, A, Fioritoni, G, Miraglia, E, Annino, L, Mosna, F, Cantore, N, Luppi, M, Nobile, F, Leone, G, Depaoli, L, Peta, A, Martelli, Ma, Majolino, I, Montanaro, M, Milella, M, Meloni, G, Foa, Roberto, and Tafuri, Agostino

Published
2005

226. Cell Kinetic, Molecular and Clinical Analysis of Growth Factor Sensitization of Myeloid Leukemia1

Author

Andreeff, Michael, primary, Drach, Johannes, additional, Zhao, Shourong, additional, Consoli, Ugo, additional, Escudier, Susan, additional, Sanchez-Williams, Gisela, additional, Liu, Yanrong, additional, Goodacre, Angela, additional, Drach, Doris, additional, Dunne, Cathleen, additional, Tafuri, Agostino, additional, Estey, Elihu, additional, and Deisseroth, Albert, additional

Full Text
View/download PDF

228. MDR1/P-gp expression predicts achievement of remission in adult acute lymphoblastic leukemia patients treated according to the GIMEMA 0496 protocol

Author

Petrucci, Mt, Gregorj, C, Ricciardi, Maria Rosaria, Mancini, M, Cimino, Giuseppe, Mecucci, C, Tedeschi, A, Fioritoni, G, Ferrara, F, Di Raimondo, F, Gallo, E, Liso, V, Fabbiano, F, Cascavilla, N, Pizzolo, G, Camera, A, Pane, F, Lanza, F, Cilloni, D, Annino, L, Vitale, A, Vegna, Ml, Vignetti, M, Foà, R, and Tafuri, Agostino

Published
2002

234. An Unsupervised Machine Learning Method Stratifies Chronic Lymphocytic Leukemia Patients in Novel Categories with Different Risk of Early Treatment

Author

Cuturello, Francesca, Pozzo, Federico, Villegas Garcia, Edith Natalia, Rossi, Francesca Maria, Degan, Massimo, Nanni, Paola, Cattarossi, Ilaria, Zaina, Eva, Varaschin, Paola, Braida, Alessandra, Berton, Michele, Zannier, Laura, Vit, Filippo, Tissino, Erika, Bittolo, Tamara, Laureana, Roberta, D'Arena, Giovanni, Laurenti, Luca, Tafuri, Agostino, Olivieri, Jacopo, Zaja, Francesco, Chiarenza, Annalisa, Del Principe, Maria Ilaria, Bomben, Riccardo, Zucchetto, Antonella, Cozzini, Stefano, Ansuini, Alessio, Cazzaniga, Alberto, and Gattei, Valter

Published
2022
Full Text
View/download PDF

235. The CXCR4dim/CD5bright Proliferative Fraction Reappears in Relapsed CLL Under Ibrutinib, Enriched in BTK Mutations

Author

Pozzo, Federico, Forestieri, Gabriela, Ianna, Giulia, Vit, Filippo, Tissino, Erika, Bittolo, Tamara, Terzi Di Bergamo, Lodovico, Laureana, Roberta, Tafuri, Agostino, Chiarenza, Annalisa, Di Raimondo, Francesco, Olivieri, Jacopo, Zaja, Francesco, Laurenti, Luca, Del Principe, Maria Ilaria, Bomben, Riccardo, Zucchetto, Antonella, Rossi, Davide, and Gattei, Valter

Published
2022
Full Text
View/download PDF

237. The CXCR4dim/CD5brightProliferative Fraction Reappears in Relapsed CLL Under Ibrutinib, Enriched in BTK Mutations

Author

Pozzo, Federico, Forestieri, Gabriela, Ianna, Giulia, Vit, Filippo, Tissino, Erika, Bittolo, Tamara, Terzi Di Bergamo, Lodovico, Laureana, Roberta, Tafuri, Agostino, Chiarenza, Annalisa, Di Raimondo, Francesco, Olivieri, Jacopo, Zaja, Francesco, Laurenti, Luca, Del Principe, Maria Ilaria, Bomben, Riccardo, Zucchetto, Antonella, Rossi, Davide, and Gattei, Valter

Published
2022
Full Text
View/download PDF

238. The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms

Author

Ciuffreda, Ludovica, Di Sanza, Cristina, Cesta Incani, Ursula, Eramo, Adriana, Desideri, Marianna, Biagioni, Francesca, Passeri, Daniela, Falcone, Italia, Sette, Giovanni, Bergamo, Paola, Anichini, Andrea, Sabapathy, Kanaga, Mccubrey, James A., Ricciardi, Maria Rosaria, Tafuri, Agostino, Blandino, Giovanni, Orlandi, Augusto, De Maria Marchiano, Ruggero, Cognetti, Francesco, Del Bufalo, Donatella, Milella, Michele, De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583), Ciuffreda, Ludovica, Di Sanza, Cristina, Cesta Incani, Ursula, Eramo, Adriana, Desideri, Marianna, Biagioni, Francesca, Passeri, Daniela, Falcone, Italia, Sette, Giovanni, Bergamo, Paola, Anichini, Andrea, Sabapathy, Kanaga, Mccubrey, James A., Ricciardi, Maria Rosaria, Tafuri, Agostino, Blandino, Giovanni, Orlandi, Augusto, De Maria Marchiano, Ruggero, Cognetti, Francesco, Del Bufalo, Donatella, Milella, Michele, and De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583)

Abstract

The mitogen-activated protein kinase (MAPK) and PI3K pathways are regulated by extensive crosstalk, occurring at different levels. In tumors, transactivation of the alternate pathway is a frequent "escape" mechanism, suggesting that combined inhibition of both pathways may achieve synergistic antitumor activity. Here we show that, in the M14 melanoma model, simultaneous inhibition of both MEK and mammalian target of rapamycin (mTOR) achieves synergistic effects at suboptimal concentrations, but becomes frankly antagonistic in the presence of relatively high concentrations of MEK inhibitors. This observation led to the identification of a novel crosstalk mechanism, by which either pharmacologic or genetic inhibition of constitutive MEK signaling restores phosphatase and tensin homolog (PTEN) expression, both in vitro and in vivo, and inhibits downstream signaling through AKT and mTOR, thus bypassing the need for double pathway blockade. This appears to be a general regulatory mechanism and is mediated by multiple mechanisms, such as MAPK-dependent c-Jun and miR-25 regulation. Finally, PTEN upregulation appears to be a major effector of MEK inhibitors' antitumor activity, as cancer cells in which PTEN is inactivated are consistently more resistant to the growth inhibitory and anti-angiogenic effects of MEK blockade. © 2012 Springer-Verlag.

Published
2012

239. t(4;11)(q21;p15) translocation involving NUP98 and RAP1GDS1 genes: characterization of a new subset of T acute lymphoblastic leukaemia

Author

Mecucci, C., LA STARZA, R., Negrini, M., Sabbioni, S., Crescenzi, B., Leoni, P., DI RAIMONDO, F., Krampera, M., Cimino, Giuseppe, Tafuri, Agostino, Cuneo, A., Vitale, A., and Foa, Roberto

Subjects
Adult, Adolescent, Molecular Sequence Data, Trisomy, Translocation, Genetic, In Situ Nick-End Labeling, Guanine Nucleotide Exchange Factors, Humans, Leukemia-Lymphoma, Adult T-Cell, Amino Acid Sequence, p15), t(4, 11)(q21, NUP98–RAP1GDS1, T-ALL, In Situ Hybridization, Fluorescence, Base Sequence, Reverse Transcriptase Polymerase Chain Reaction, Chromosomes, Human, Pair 11, Membrane Proteins, Nuclear Proteins, Artificial Gene Fusion, Nuclear Pore Complex Proteins, Karyotyping, Female, Chromosomes, Human, Pair 4, Chromosomes, Human, Pair 8
Abstract

Two cases of T acute lymphoblastic leukaemia (T-ALL) with an identical t(4;11)(q21;p15) translocation were identified within a prospective study on the biological and clinical features of adult ALL patients enrolled into the therapeutic protocol ALL0496 of the GIMEMA Italian Group. In both cases, the molecular characterization showed an involvement of the NUP98 gene on 11p15 which rearranges with the RAP1GDS1 gene on 4q21. The morphological and immunological features of the leukaemic cells, as well as the clinical behaviour and response to induction therapy, were the same in both patients. Based on the available data, the t(4;11)(q21;p15) translocation involving the NUP98-RAP1GDS1 fusion gene emerges as a new highly specific genetic abnormality that characterizes a subset of T-ALL.

Published
2000

Catalog

Books, media, physical & digital resources
See catalog results